Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases.

Catalano V, Bisonni R, Graziano F, Giordani P, Alessandroni P, Baldelli AM, Casadei V, Rossi D, Fedeli SL, D'Emidio S, Giustini L, Fiorentini G.

Gastric Cancer. 2013 Jul;16(3):411-9. doi: 10.1007/s10120-012-0204-z. Epub 2012 Oct 11.

PMID:
23065042
2.

FOLFOX (oxaliplatin and 5 fluorouracil/leucovorin) in patients with untreated metastatic gastric adenocarcinoma Phase II study.

Mohammad HA, Magdy FM, Mahmoud OM.

Indian J Cancer. 2011 Oct-Dec;48(4):460-5. doi: 10.4103/0019-509X.92280.

3.

[FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].

Yan D, Dai H.

Zhonghua Zhong Liu Za Zhi. 2009 Mar;31(3):217-9. Chinese.

PMID:
19615264
4.

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.

De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, Damiano V, Simeone E, Diadema MR, Lieto E, Castellano P, Pepe S, De Placido S, Galizia G, Di Martino N, Ciardiello F, Catalano G, Bianco AR.

Br J Cancer. 2005 May 9;92(9):1644-9.

5.

Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.

Tsuji K, Yasui H, Onozawa Y, Boku N, Doyama H, Fukutomi A, Yamazaki K, Machida N, Todaka A, Taniguchi H, Tsushima T, Yokota T.

Jpn J Clin Oncol. 2012 Aug;42(8):686-90. doi: 10.1093/jjco/hys084. Epub 2012 Jun 11.

PMID:
22693245
6.

Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer.

Cho YH, Kim SY, Hong Lee M, Yoo MW, Bang HY, Lee KY, Yoon SY.

Gastric Cancer. 2012 Oct;15(4):389-95. doi: 10.1007/s10120-011-0128-z. Epub 2012 Jan 12.

PMID:
22237658
7.

A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.

Luo HY, Xu RH, Zhang L, Li YH, Shi YX, Lin TY, Han B, Wang F, Qiu MZ, He YJ, Guan ZZ.

Chemotherapy. 2008;54(3):228-35. doi: 10.1159/000140467. Epub 2008 Jun 18.

PMID:
18560231
8.

Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status.

Petrioli R, Francini E, Roviello F, Marrelli D, Miano ST, Fiaschi AI, Laera L, Bellini MA, Roviello G.

J Geriatr Oncol. 2015 Sep;6(5):380-6. doi: 10.1016/j.jgo.2015.06.002. Epub 2015 Jul 27.

PMID:
26228711
9.

A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer.

Zhao JG, Qiu F, Xiong JP, Zhang L, Xiang XJ, Yu F, Yan J, Zhan ZY, Feng M.

Anticancer Drugs. 2009 Apr;20(4):281-6. doi: 10.1097/CAD.0b013e328324bbc1.

PMID:
19247179
10.

A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma.

Xiang XJ, Liu YW, Zhang L, Qiu F, Yu F, Zhan ZY, Feng M, Yan J, Zhao JG, Xiong JP.

Anticancer Drugs. 2012 Jun;23(5):561-6. doi: 10.1097/CAD.0b013e328350dd0d.

PMID:
22481063
11.

A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.

Xiong JP, Zhang L, Zhong LX, Qiu F, Xu J, Tao QS, Xiang XJ, Yu F, Tang XM.

Anticancer Drugs. 2007 Oct;18(9):1103-7.

PMID:
17704661
12.

Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer.

Liu ZF, Guo QS, Zhang XQ, Yang XG, Guan F, Fu Z, Wang MY.

Am J Clin Oncol. 2008 Jun;31(3):259-63. doi: 10.1097/COC.0b013e31815d43ee.

PMID:
18525305
13.

A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.

Oh SY, Kwon HC, Lee S, Lee DM, Yoo HS, Kim SH, Jang JS, Kim MC, Jeong JS, Kim HJ.

Jpn J Clin Oncol. 2007 Dec;37(12):930-5. doi: 10.1093/jjco/hym131.

PMID:
18211984
14.

Modified FOLFOX-4 as first-line and salvage treatment in advanced gastric cancer.

Baek YH, Choi SR, Jang JS, Roh MH, Lee JH, Won JJ, Lee CM.

Hepatogastroenterology. 2011 Jan-Feb;58(105):251-6.

PMID:
21510324
15.

A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer.

Chiesa MD, Buti S, Tomasello G, Negri F, Buononato M, Brunelli A, Lazzarelli S, Brighenti M, Donati G, Passalacqua R.

Tumori. 2007 May-Jun;93(3):244-7.

16.

Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.

Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, Park JO, Kim SY, Kim TY, Kim JH, Ahn JB, Lim SB, Yu CS, Kim JC, Yun SH, Kim JH, Park JH, Park HC, Jung KH, Kim TW.

Lancet Oncol. 2014 Oct;15(11):1245-53. doi: 10.1016/S1470-2045(14)70377-8. Epub 2014 Sep 4.

PMID:
25201358
17.

A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.

Kim BG, Oh SY, Kwon HC, Lee S, Lee DM, Kim SG, Kim DK, Jang JS, Kim MC, Kim SH, Kim HJ.

Am J Clin Oncol. 2010 Jun;33(3):246-50. doi: 10.1097/COC.0b013e3181a650d4.

PMID:
19770628
18.

[Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer].

Kwon HJ, Park MI, Park SJ, Moon W, Kim SE, Lee HW, Choi YJ, Kim JH.

Korean J Gastroenterol. 2015 Jul;66(1):10-6. doi: 10.4166/kjg.2015.66.1.10. Korean.

19.

Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.

Lim JY, Cho JY, Oh KJ, Choi SH, Lee SI, Jeung HC.

Chemotherapy. 2009;55(4):200-6. doi: 10.1159/000219434. Epub 2009 May 19.

PMID:
19451710
20.

Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.

Spigel DR, Greco FA, Waterhouse D, Shipley D, Lane CM, Vazquez ER, Clark BL, Infante JR, Bendell JC, Burris HA 3rd, Hainsworth JD.

Clin Adv Hematol Oncol. 2010 Jul;8(7):480-5, 498.

PMID:
20864916

Supplemental Content

Support Center